Expedition Therapeutics Closes $115 Million Series B
· vcnewsdaily.com
SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B financing.
Expedition Therapeutics Closes $115 Million Series B Back to Home
SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing...